C/EBP Homologous Protein Deficiency Attenuates Myocardial Reperfusion Injury by Inhibiting Myocardial Apoptosis and Inflammation

Yuji Miyazaki(IRYO Sosei University), Yuichi Oike(Kumamoto University), Kenichi Tsujita(British Heart Foundation), Tomomi Gotoh(IRYO Sosei University), Motoyoshi Endo(IRYO Sosei University), Seiji Hokimoto(Omuta hospital), Eiji Horio(Kumamoto University), Koichi Kaikita(Kumamoto University), Megumi Yamamuro(IRYO Sosei University), Hisao Ogawa(Jikei University School of Medicine), Mitsutoshi Miura(IRYO Sosei University), Takao Iwawaki(Gunma University)
Arteriosclerosis Thrombosis and Vascular Biology
February 18, 2011
10.1161/atvbaha.111.224519
Cited by 142

Related Papers

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial
|The Lancet|2017|1.3k
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial
|The Lancet|2017|881
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|449